Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
Cytokinetics, IncorporatedDecember 14, 2020 GMT
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data relating to the impact of patient characteristics on treatment effect in FORTITUDE-ALS, the Phase 2 clinical trial of
reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), were presented at the 31st International Symposium on ALS/MND. Additionally, the company announced that the design of COURAGE-ALS (Clinical Outcomes Using
R
eldesemtiv on ALSFRS-R in a Global Evaluation in ALS), a planned Phase 3 clinical trial of